The addition of a programmed death ligand 1 inhibitor to standard chemotherapy as first-line treatment of patients with advanced non-small-cell lung cancer results in significantly longer overall survival and progression-free survival.

Conferences

Patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed while on crizotinib (CRZ) may experience improved response rates when treated with the investigational tyrosine kinase inhibitor brigatinib, according to results presented at the 2016 American Society of Clinical Oncology Annual Meeting (June 3-7; Chicago, IL).

Read More

The addition of plinabulin to non-small cell lung cancer (NSCLC) treatment with docetaxel may reduce the frequency of adverse events and help prevent dose reductions due to toxicity, according to an abstract at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL (June 3-7, 2016).

Read More

Including certain quality measures as a part of care for patients with non-small cell lung cancer (NSCLC) who undergo surgery can significantly improve survival, according to results presented at the American Association for Thoracic Surgery Annual Meeting (May 14-18, 2016; Baltimore, MD).

Read More

Using stereotactic body radiation therapy (SBRT) to treat patients with non-small cell lung cancer (NSCLC) may slightly increase the risk of dying from a cause other than cancer, according to research presented at European Society for Radiotherapy and Oncology (ESTRO) 35 (April 29-May 3, 2016; Turin, Italy).

Read More

News

The addition of a programmed death ligand 1 inhibitor to standard chemotherapy as first-line treatment of patients with advanced non-small-cell lung cancer results in significantly longer overall survival and progression-free survival.
An immunotherapy plus chemotherapy combination regimen improves overall survival in patients with advanced non-squamous non-small cell lung cancer.
The combination of atezolizumab plus chemotherapy improved progression-free survival compared with chemotherapy alone in the first-line setting for patients with advanced squamous non-small cell lung cancer.
Targeted next-generation sequencing may help estimate tumor mutation burden and predict the likelihood of benefit with immune checkpoint inhibitors in advanced non-small cell lung cancer.

Research in Review

A second-generation inhibitor delays anaplastic lymphoma kinase (ALK)-positive lung cancer growth for a median of 15 months longer and causes fewer adverse events than the current standard of care, according to a new study presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Few patients treated with immunotherapy for metastatic non–small cell lung cancer (NSCLC) at United States community practices receive appropriate programmed death-ligand 1 (PD-L1) expression testing, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Patients with non-small cell lung cancer (NSCLC) and synchronous brain metastasis demonstrate improved 1-year and 5-year overall survival (OS) after thoracic surgery and systemic chemotherapy, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Patients with advanced non-small cell lung cancer (NSCLC) who receive previous radiotherapy are more likely to benefit from immunotherapy than those patients without previous radiotherapy, according to research published in The Lancet (published online May 24, 2017; doi:10.1016/S1470-2045(17)30380-7).

-----

Related Content

Read More

Special Reports

This report will help oncology care providers understand the significance of ALK gene rearrangements for NSCLC as well as the potential benefits of ALK inhibition in relapsed or refractory settings.
Subscribe to Non-Small Cell Lung Cancer